TRY NOW

Enhance and accelerate your early stage research with trusted and comprehensive intelligence from Thomson Reuters.

Start your free trial in just two simple steps.

Get your FREE trial

Enrich your discovery science with market leading, manually curated scientific intelligence. Systems Biology, Preclinical, Biomarkers, Chemistry, Biology, and Pharmacology - and everything in between. Covered from the perspective that matters most – yours.
Customer Feedback
Customer Feedback

Annette Bakker, Chief Scientific Officer from CTF, explains the reasons why she likes to work with Thomson Reuters. Currently using MetaCore™ to identify disease treatment options.

Live & Recorded Training

Attend one of our regularly scheduled webinar training sessions for overviews of features, tools, and content – find the schedule here

Free Pathway Maps

Search or browse through a wide range of proprietary multi-step canonical pathway maps here.

Featured News

The latest news from Life Sciences Research
The future of COPD treatment

The future of COPD treatment

Our research shows greater focus on preventative therapies

Translational Medicine

Translational Medicine

Supplement-Size Doses of Antioxidants Hasten Lung Cancer Progression

Tet Proteins Erase Epigenetic Marks

Tet Proteins Erase Epigenetic Marks

It is (reasonably) common knowledge that DNA is written in a simple four-letter code: ACTG. Too simple, actually.

Blog Highlights

Read our latest blog posts

Global Regulatory Environment: Hazards Ahead!

One of the largest regulatory events of the year is right around the corner. As you prepare for the DIA 2015 51st Annual Meeting this ...

Glybera Hails in a New Era in Gene Therapy

Gene therapy is rapidly becoming big business, with a deluge of deals, increasing investment by large pharmaceutical companies and stock market debuts. This approach holds ...

Companion Diagnostics: How Pharma and Biotech Medical Device Companies are Responding

Companion Diagnostics are medical tests that identify patients within a disease category who are most likely to positively respond to a particular drug, given that ...

Whitepapers & Publications

View our recent whitepapers and publications

BioMarker White Paper

Biomarkers: An indispensible addition to the drug development toolkit

THE YEAR'S NEW DRUGS & BIOLOGICS, 2013: PART I

http://dx.doi.org/10.1358/dot.2014.50.1.2116673

Latest on Twitter

Latest on Linked In